Circulating endothelial progenitor cells during pregnancy in multiple sclerosis

Giulia Mallucci1,2, Fausta Beneventi3, Roberto Bergamaschi2, Cristina Bizzotto2, Chiara Cavagnoli3, Irene De Maggio3, Camilla Bellingeri3, Cristina Monti4, Gianluca Viarengo5, Arsenio Spinillo3

Received: 11 April 2020 / Accepted: 1 August 2020 / Published online: 17 August 2020 © The Author(s) 2020

Abstract

Background Endothelial progenitor cells (EPCs) have been shown to increase during physiological pregnancy and are believed to play a fundamental role in the process of placentation. Reduced levels of EPCs during pregnancy have been associated with preeclampsia and miscarriage. Women with multiple sclerosis (MS) are not at increased risk of preeclampsia nor of general adverse obstetric outcome, in contrast with some other autoimmune diseases.

Objective The aim of this study was to evaluate circulating EPCs levels in pregnant patients with MS.

Methods CD34+ and CD133+ were longitudinally detected by flow cytometry in the maternal plasma of 29 healthy controls and 9 MS patients and in the cord blood of their newborns.

Results EPCs were affected by pregnancy with the same trend in both groups (CD34+ p = 0.0342; CD133+ p = 0.0347). EPCs during pregnancy were increased in MS (mean ± SD: CD34+ cells 0.038 ± 0.010; CD133+ 0.024 ± 0.009) with respect to healthy controls (mean ± SD: CD34+ cells 0.022 ± 0.006; CD133+ 0.016 ± 0.004), CD34+ p = 0.0004; CD133+ p = 0.0109. EPCs levels of the cord blood of MS patients' newborns mild correlated with maternal EPC levels at delivery (CD34+: spearman’s Rho 0.658, p = 0.054; CD133+: spearman’s Rho 0.758, p = 0.018).

Conclusions This work identified increased circulating EPC levels during pregnancy, following the same trend both in MS patients and healthy controls. Despite the similar trend, the levels of circulating EPCs were significantly higher in MS patients with respect to the control population. A correlation was also found in MS patients between cord blood EPCs and circulating EPCs at delivery.

Keywords Multiple sclerosis · Pregnancy · Circulating endothelial progenitor cells · EPC · Cord blood

Giulia Mallucci and Fausta Beneventi should be considered joint first author

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10072-020-04648-3) contains supplementary material, which is available to authorized users.

Giulia Mallucci giulia.mallucci@mondino.it

1 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
2 Multiple Sclerosis Center, IRCCS Mondino Foundation, Via Mondino 2, 27100 Pavia, Italy
3 Department of Obstetrics and Gynaecology, IRCCS Foundation Policlinico San Matteo and University of Pavia, Pavia, Italy
4 Department of Public Health Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy
5 Immunohaematology and Transfusion Service, IRCCS Foundation Policlinico San Matteo, Pavia, Italy
Introduction

Multiple sclerosis (MS) is a chronic inflammatory and degenerative demyelinating disease of the central nervous system of presumed autoimmune aetiology [1, 2]. The disease mainly affects young women of childbearing age, and more recent data show that more than 50% of childbearing age MS women get pregnant after diagnosis [3].

Pregnancy has a protective effect on MS course, progressively decreasing the risk of relapses up to 70% by the end of the third trimester due to multiple factors, which are likely successively decreasing the risk of relapses up to 70% by the end of terms of disability [5]. Vice versa, MS does not seem to affect pregnancy and of adverse pregnancy outcomes are not significantly different compared with healthy controls [6, 7].

Circulating endothelial progenitor cells (EPCs), expressing CD34 and CD133, are believed to play a significant role both in vasculogenesis and vascular repair. Since their identification by Asahara et al. in 1997 [8], most studies on EPCs focused on their role in cardiovascular health and on their potential therapeutic applications [9].

During uncomplicated pregnancy, the number of circulating EPCs seems to increase, possibly as a result of neoangiogenesis that occurs during placentation [10–12]. On the other hand, a decreased number of circulating EPCs have been associated with preeclampsia, a disease notably characterized by defective placental vascularization [10, 13] and with increased risk of miscarriage [14, 15].

Endothelial dysfunction is a known feature of some autoimmune connective tissue diseases; altered levels and function of EPCs have been detected in rheumatoid arthritis (RA), systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) [16–21]. Interestingly, these conditions are associated with increased risk of adverse obstetric outcome [22–24].

MS shares several features with RA, SSc and SLE, notably the autoimmune component. However, unlike other autoimmune diseases, MS patients are not at increased risk of general adverse obstetric outcome nor of foetal or neonatal complications [6, 7]. The assessment of circulating EPC levels during pregnancy in MS patients may shed some light on the difference observed in pregnancy outcome favourability in MS patients relative to that observed in patients diagnosed with other autoimmune diseases.

Materials and methods

This non-interventional prospective study was approved by the medical ethics committee of IRCCS Policlinico San Matteo of Pavia (Current Research Project N. 10,901-rcr2017i-23 years 2017–2020) and was conducted according to the principles of the Declaration of Helsinki.

The study was run in collaboration between the Department of Obstetrics and Gynecology, IRCCS Policlinico San Matteo Pavia, and the MS Centre, IRCCS Mondino Foundation of Pavia.

Patients and controls

A total of 38 subjects, 9 relapsing remitting MS patients (MS) and 29 healthy controls (CTRL), were enrolled in the study at 11–13 weeks of gestation from April 2017 to April 2019. All recruited subjects signed an informed consent form. MS patients had diagnosis according to McDonald Criteria [25]. Three controls for each MS case were selected from obstetrics, frequency-matched by age. Healthy controls and MS patients were prospectively followed up until delivery. Neither multiple pregnancies nor pregnancies with chromosomal or foetal abnormalities were observed in these 38 subjects.

Neurological outcome

According to clinical practice, a neurological exam was performed during the first trimester (i.e. 11–13 weeks of gestation) and the third trimester (i.e. 28–32 weeks of gestation). During the first trimester consult, medical history, MS history, demographic and clinical data were also recorded. At each examination, Expanded Disability Status Scale (EDSS) [26], MS relapses, MS radiological activity and adverse events (AE) were reported. None of the MS patients was on treatment for MS (disease modifying treatment, DMT) during pregnancy or lactation. MS relapse was defined as an episode of neurological symptoms that lasts at least 24 h in the absence of fever and infection. MS radiological activity was defined as contrast-enhanced lesions or the appearance of new T2-hyperintense lesions, compared with the previous scan. Chronic disability progression (CDP) was defined as (i) ≥ 1.5-point increase if EDSS = 0 at baseline, or (ii) ≥ 1.0-point increase if EDSS = 0.5–4.5 at baseline, or (iii) ≥ 0.5-point increase if EDSS ≥ 5.0 at baseline, confirmed at 3 months. NEDA-3 (no evidence of disease activity) status was reported [27]. In detail, the three assessed components were (i) no CDP, (ii) no relapse activity, and (iii) no radiological activity.

Obstetric outcome

After the first trimester (enrolment), MS patients and CTRL were followed up monthly with obstetric clinical and ultrasonographic evaluations.

Foetal growth restriction (FGR) was diagnosed when the abdominal foetal circumference at ultrasonographic examination fell below the 10th percentile of our local reference curves [28], confirmed on at least two consecutive measurements.
than the 95th percentile of reference curves. Pre-eclampsia was diagnosed according to standard criteria. Stored maternal blood samples from first (11–13 weeks) and third (28–32 weeks) trimesters and delivery and stored cord blood were used to evaluate EPC count.

The mean uterine artery PI was evaluated in the first and third trimesters according to standard methods. PI of uterine arteries was considered abnormal when the values were higher than the 95th percentile of reference curves.

**Blood samples processing**

Blood was collected from different participants at 11–13 weeks (first trimester), at 28–32 weeks (third trimester), at delivery and from cord blood and was used to evaluate EPC count.

Blood samples were freshly analysed by lyse-and-wash whole blood staining procedure. Surface staining was performed on ice for 20 min, and the cells were then analysed on a two-laser, six-colour FACSCanto flow cytometer. Multiplexed dilutions of monoclonal antibodies (mAbs) were used to characterize lymphocyte populations.

**Flow cytometry**

The populations of CD34+ and CD133+ endothelial progenitor cells were measured by flow cytometry utilizing a Beckman Coulter Navios (Indianapolis, IN, USA) and were expressed as percent cell count/μL. The following antibodies were used: anti CD45 FITC and anti CD34 PE by Beckman Coulter (Indianapolis IN, USA), anti CD133 APC by Miltenyi Biotec (Bergisch Gladbach, Germany). The software utilized for acquisitions and analyses was Beckman Coulter Navios Software (Indianapolis IND, USA).

The positive population for both CD34 and CD133 antigens has been defined by a Boolean strategy utilizing three dot plots: CD45 vs side scatter to define leukocytes, CD34 vs side scatter to reveal CD34 positive cells and CD133 vs side scatter for CD133 positive cells.

**Statistical analyses**

The feature description was summarized by the appropriate descriptive statistics. The comparison between MS and CTRL demographical and clinical characteristics was evaluated by Mann-Whitney U test or unpaired Student t test, as appropriate, for quantitative variables; chi-square or Fisher exact tests were applied to explore categorical variables’ differential distribution.

To study the variation of CD34+ and CD133+ cells’ endpoint variables during pregnancy, a non-parametric approach was chosen, composed by three steps. (1) Friedman test was used for the evaluation of the effect of gestational age (repeated time points for each woman: 11–13, 28–32 gestational weeks and time of delivery) independently from the effect of clinical status, followed, when significant, by post hoc sign tests with correction for multiple comparisons. (2) Mann-Whitney U tests were carried out, for the evaluation of the effect of clinical status, independently from the gestational age effect. Specifically, we compared the global median value of CD34+ and CD133+ cells between MS and CTRL, followed by the post hoc comparisons at the different gestational time points. (3) The statistical interaction between gestational age and clinical status (MS versus CTRL) was evaluated by graphical techniques.

To study the variation of CD34+ and CD133+ cells’ endpoint variables in the cord blood, we used Mann-Whitney U test. Spearman’s rank correlation was used to identify a correlation between CD34+ and CD 133+ cells at delivery and in the cord blood.

A p value below 0.05 was considered statistically significant. All the analyses were performed using the STATA 15 statistical software (Stata Corporation, College Station, TX, USA).

**Results**

**Demographic and clinical characteristics of MS patients and CTRL**

All 38 participants completed the study. There were no dropouts, and none of the included participants was excluded from the analysis.

Demographic and clinical characteristics of individuals are summarized in Table 1. Age and parity were not significantly different between MS and CTRL, as well as gestational age, BMI, smoking/alcohol habits and rates of pregnancy complications. The frequency of previous miscarriages was increased in MS compared with CTRL, but within the healthy range [30]. Birth weight was higher in MS patients compared with CTRL but within the physiological range.

Among MS patients, 6 out of 9 (67%) were NEDA 1 year before the onset of pregnancy, and 5 (55%) were NEDA 2 years before the onset of pregnancy. Mean MS duration at pregnancy was 8.33 ± 4.33 years. Median EDSS during the first trimester was 1.0 (min-max: 0–3.5) and during third trimester was 1.0 (min-max: 0–3.5). None of MS patients had a clinical relapse during pregnancy, but disease activity within 3 months from delivery was registered in 1/3 of patients. EDSS 3 months postpartum was 1.0 (min-max: 0–4.0). Clinical characteristics of individuals are summarized in Fig. 1.
CD34 and CD133 population

A total of 114 observations (three observations per individual) were available for analysis.

As illustrated in Fig. 2 and Fig. 3, both clinical status (MS versus healthy controls) and gestational age influenced progenitor cells levels during pregnancy.

EPCs were significantly higher in MS group compared with healthy controls. Specifically, the CD34+ median expression levels were 0.040 (IQR 0.030–0.046) among MS and 0.023 (IQR 0.020–0.026) among CTRL \((p = 0.0004)\), whereas the CD133+ median expression levels were 0.233 (IQR 0.020–0.030) in the MS group and 0.016 (IQR 0.013–0.020) in the CTRL group \((p = 0.0109)\).

In details, analysis highlighted that in MS group compared with healthy control group, mean CD34+ cells are increased by 47.9% \((p = 0.030)\), 96.1% \((p = 0.010)\), and 63.7% \((p = 0.027)\) during the first trimester, the third trimester and at delivery, respectively (Fig. 1 supplement). Mean CD133+ cells are increased by 50.3% \((p = 0.190)\), 55.4% \((p = 0.116)\) and 33.3% \((p = 0.113)\) during the first trimester, the third trimester and at delivery, respectively (Fig. 2 supplement).

Additionally, time significantly affects levels of EPCs (CD34+: median first trimester 0.020 IQR 0.020–0.040, median third trimester 0.030 IQR 0.020–0.030; median at delivery 0.020 IQR 0.020–0.030, \(p = 0.0342\); CD133+: median first trimester 0.015 IQR 0.010–0.020, median third trimester 0.020 IQR 0.010–0.030; median at delivery 0.010 IQR 0.010–0.020, \(p = 0.0347\)).

In particular, analysis highlighted that CD34+ and CD133+ cells in CTRL group were lower at delivery compared with the third trimester (24.3% lower, \(p < 0.001\) and 26.9%, \(p < 0.001\), respectively); and CD133+ cells were higher during the third trimester compared with the first trimester \((p = 0.047)\). No statistical difference was observed in MS group.

Progenitor levels at all time point were not associated with MS outcome (i.e. relapse free; number of relapses, radiological activity and EDSS) neither before pregnancy, nor during pregnancy, nor after pregnancy.

In both groups, we did not observe any correlation between progenitors and mean uterine artery Doppler PI, neither at first trimester nor at third trimester.

Cord blood

A total of 38 observations (one observation per individual) were available for analysis. Clinical status (MS versus healthy controls) did not influence progenitors in cord blood.

Specifically, the CD34+ median expression levels were 0.390 (IQR 0.120–0.500) in MS group and 0.210 (IQR 0.170–0.240) in CTRL group \((p = 0.203)\), whereas the CD133+ median expression levels were 0.240 (IQR 0.120–0.400) in the MS group and 0.120 (IQR 0.110–0.160) in the CTRL group.

Maternal CD34+ cells at delivery mildly correlated with CD34+ in the cord blood neither in MS patients (Spearman’s Rho 0.658, \(p = 0.054\)) but not in CTRL (Spearman’s Rho 0.069, \(p = 0.723\)). Maternal CD133+ at delivery positively correlated with CD133+ in the cord blood in MS patients (Spearman’s Rho 0.758, \(p = 0.018\)) but not in CTRL (Spearman’s Rho 0.006, \(p = 0.976\)). Correlation plots are illustrated in Fig. 4 and Fig. 5.

Discussion

Pregnancy in autoimmune diseases often requires a multidisciplinary approach to prevent and monitor maternal, foetal and neonatal issues [31, 32]. MS is no exception and pregnancy should be carefully planned, in order to optimize therapy and

### Table 1. Obstetrics outcomes of the study sample by clinical status. BMI = body mass index; CTRL = healthy control; MS = multiple Sclerosis; SGA = small for gestational age; NICU = neonatal intensive care unit; SD = standard deviation. Tests applied: \(^*\)Mann–Whitney U test; \(^\ddagger\)Pearson’s test; \(^\S\)Fisher exact test.

|                        | MS \((n = 9)\) | CTRL \((n = 28)\) | \(p\) value |
|------------------------|---------------|-------------------|-------------|
| Age, years, mean (SD)  | 32.33 (4.90)  | 32.38 (4.81)      | 1.000*      |
| Nulliparous            | 5 (55.5)      | 8 (28.57)         | 0.122\^\ddagger |
assess whether disease activity advises conception [33]. Contrary to several autoimmune diseases, MS patients are not at increased risk of pregnancy complications, such as pre-eclampsia, nor of general adverse obstetric outcome, nor of foetal or neonatal complications, even though some studies reported a slightly higher rate of preterm labour for these patients [6, 7]. In our study, there were no preterm labours. The evaluation of circulating EPCs may offer a hint on the marked difference in outcome favourability in MS patients with respect to patients affected by other autoimmune conditions.

Circulating EPCs are reduced in RA [16, 17], and the risk of spontaneous abortion seems to be higher in patients with RA [22] with respect to women without RA. In SSc, available data suggests that EPCs are recruited early in the course of disease during active inflammation, but as the disease progresses further, circulating EPC levels were shown to decrease, possibly as a result of their progressive depletion [18–20]. Women with SSc present higher frequency of adverse events during pregnancy, including miscarriage, intrauterine growth restriction and gestational hypertension [23]. Reduced levels of EPCs were found in patients affected by SLE [21]; in patients with SLE, pregnancy is considered at high risk, both for the maternal and foetal outcome [24].

Thus, in the present study, EPCs were evaluated during pregnancy in healthy women and patients with MS. To our knowledge, this is the first study which not only longitudinally
analyses the expression of circulating EPCs in pregnant women with MS and in cord blood of their newborns but also which healthy controls and MS patients were referred to the same third level obstetric and third level MS Centre enhancing homogenous evaluation and data quality.

This work identified increased circulating EPC levels during pregnancy, following the same trend both in MS patients and in healthy controls. Despite the similar trend, the levels of circulating EPCs were significantly higher in MS patients with respect to the control population. Although the exact function of EPCs in pregnancy remains largely unexplored and requires further characterization, current knowledge suggests that these cells play a role in the correct development and functioning of the uteroplacental circulation promoting spiral artery remodelling. EPCs can be mobilized by several factors that notably increase during pregnancy, such as vascular endothelial growth factor, placental growth factor and oestrogen. To date, an increase in circulating EPCs during normal pregnancy has been reported by several studies [10–12]. Fewer authors observed an opposite trend, in contrast with the majority of literature [34].

The absence of a reduction in EPCs in MS pregnancies would appear to be in line with the non-increased risk of obstetric adverse events, as opposed to other conditions such as RA, SSc and SLE [6, 7]. Explaining the increased levels of EPCs observed in MS pregnant women is more challenging. Circulating EPC levels may be increased in MS patients, independently from pregnancy, or may be affected by a long-
lasting effect of previous DMT [35]. Moreover, due to the small sample size of this study, results should be interpreted carefully.

Finally, to the best of our knowledge, there are no data about levels of circulating EPCs in the cord blood of newborns of MS patients. Cord blood EPCs can be affected by several maternal factors (such as gestational period, placenta weight, delivery way, ethnicity, foetal distress, maternal diseases) and neonatal factors (such as birth weight and sex) [36]. Pre-eclampsia seems to be associated with reduced levels of circulating EPCs in cord blood, while maternal hypertension has been sporadically associated with an increased number of circulating EPCs compared to healthy controls [37].

In this regard, this study found a mild correlation between circulating maternal CD34+ and CD133+ cells at delivery and circulating CD34+ and CD133+ cells in the cord blood of the newborns of MS patients. Although it is attempting to think that this result from a “carryover” effect, with passage from the maternal unit to the maternal-foetal unit, further studies are required to address this question.

Finally, although it is the object of research in multiple fields, EPC assessment has yet to be validated as a reliable marker of vascular dysfunction. However, it can be hypothesised that if EPCs will ever enter clinical practice as markers for the monitoring of pre-eclampsia or other pregnancy complications, the findings of this work may have relevant
implications for this use of EPCs in women with MS. To this regard it is utmost importance to assess EPCs in larger groups of MS patients before conception and to evaluate EPC levels during their pregnancy and in post-partum. In fact, if women with MS tend to have higher circulating EPC levels during pregnancy with respect to healthy controls, the reference range or cut-off established in the general population may not be accurate for MS patients, who may be at increased risk of complications with higher EPCs levels, despite being in the normal range.

In conclusion, circulating EPC levels followed the same increasing trend in MS patients and healthy controls, with higher levels detected in MS patients. A correlation was found between cord blood EPCs and circulating EPCs at delivery. Further investigations in larger group of patients and focused on pre- and postpartum EPCs levels and on other inflammatory markers likely are required for the correct interpretation of these findings and to better examine the matter.

Acknowledgements Open access funding provided by Università degli Studi di Pavia within the CRUI-CARE Agreement.

Funding information This research was supported by Current Research Project N. 10 901-rcr2017i-23, years 2017–2020.

Data availability The data that support the findings of this study are available on request from the corresponding authors. The data are not publicly available due to privacy or ethical restrictions.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval This non-interventional prospective study was approved by the ethical committee of IRCCS Policlinico San Matteo of Pavia: protocol number: 08067517.

Consent to participate (include appropriate statements) Informed consent was obtained from all individual participants included in the study.

Consent for publication Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Code availability Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S (2015) The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol 127–128:1–22
2. Thompson AJ, Baranzini SE, Geurts J, Henrem B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391:1622–1636
3. Van Der Kop ML, Pearce MS, Dahlgren L et al (2011) Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 70:41–50. https://doi.org/10.1002/ana.22483
4. Voskuhl R, Montazew C (2017) Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding. Neurotherapeutics 14:974–984
5. Nguyen A-L, Eastaugh A, van der Walt A, Jokubaitis VG (2019) Pregnancy and multiple sclerosis: clinical effects across the lifespan. Autoimmun Rev 18:102360. https://doi.org/10.1016/j.autrev.2019.102360
6. MacDonald SC, McElrath TF, Hernández-Díaz S (2019) Pregnancy outcomes in women with multiple sclerosis. Am J Epidemiol 188:57–66. https://doi.org/10.1093/aje/kwy197
7. Houtchens MK, Edwards NC, Schneider G, Stern K, Phillips AL (2018) Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 91:e1559–e1569. https://doi.org/10.1212/WNL.0000000000006384
8. Ashara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(80):964–967. https://doi.org/10.1126/science.275.5302.964
9. Bianconi V, Sahebkar A, Kovanen P, Bagaglia F, Ricciuti B, Calabrò P, Patti G, Pirro M (2018) Endothelial and cardiac progenitor cells for cardiovascular repair: a controversial paradigm in cell therapy. Pharmacolet Ther 181:156–168. https://doi.org/10.1016/j.pharmthera.2017.08.004
10. Luppi P, Powers RW, Verma V, Edmunds L, Plymire D, Hubel CA (2010) Maternal circulating CD34+VEGFR-2+ and CD133+VEGFR-2+ progenitor cells increase during normal pregnancy but are reduced in women with preeclampsia. Reprod Sci 17:643–652. https://doi.org/10.1177/1933719110366164
11. Flo K, Blix ES, Husebekk A, Thomassen A, Uhre AT, Wilsgaard T, Vårtun Å, Acharya G (2016) A longitudinal study of maternal endothelial function, inflammatory response and uterine artery blood flow during the second half of pregnancy. Acta Obstet Gynecol Scand 95:225–232. https://doi.org/10.1111/aogs.12802
12. Sugawara J, Mitsui-Saito M, Hoshiai T, Hayashi C, Kimura Y, Okamura K (2005) Circulating endothelial progenitor cells during human pregnancy. J Clin Endocrinol Metab 90:1845–1848. https://doi.org/10.1210/jc.2004-0541
13. Buemi M, Allegra A, D’Anna R et al (2007) Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol 196:68.e1–68.e6. https://doi.org/10.1016/j.ajog.2006.08.032
14. Kantki K, Li M, Terai Y et al (2016) Bone marrow-derived endothelial progenitor cells reduce recurrent miscarriage in gestation. Cell Transplant 25:2187–2197. https://doi.org/10.3727/096368916X692753
15. Giordano D, Loddo S, Laganà AS, Coppolino G, Zecchi G, di Benedetto A, Santamaria A, Buemi M, D’Anna R (2018) Peripheral blood CD34+ cells as a novel and noninvasive early marker of first trimester miscarriage: results from a case-control analysis. J Matern Fetal Neonatal Med 31:258–260. https://doi.org/10.1080/14767058.2016.1277703
16. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzingar I, Woloszczuk W, Steiner G, Smolen JS (2005) Depletion of endothelial progenitor cells in the peripheral
blood of patients with rheumatoid arthritis. Circulation 111:204–211. https://doi.org/10.1161/01.CIR.0000151875.21836.AE

17. Adawi M, Pastukh N, Saaida G, Sirchan R, Watad A, Blum A (2018) Inhibition of endothelial progenitor cells may explain the high cardiovascular event rate in patients with rheumatoid arthritis. QJM 111:525–529. https://doi.org/10.1093/qjmed/hcy099

18. Nevsikaya T, Bykovskaya I, Lyssuk E et al Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol 26(3):421–429

19. Patschan S, Tampe D, Müller C, Seitz C, Herink C, Müller GA, Zeisberg E, Zeisberg M, Henze E, Patschan D (2016) Early endothelial progenitor cells (eEPCs) in systemic sclerosis (SSc) - dynamics of cellular regeneration and mesenchymal transdifferentiation. BMC Musculoskelet Disord 17:339. https://doi.org/10.1186/s12891-016-1197-2

20. Benyamine A, Magalon J, Cointe S et al (2017) Increased serum levels of fractalkine and mobilisation of CD34+CD45- endothelial progenitor cells in systemic sclerosis. Arthritis Res Ther 19. https://doi.org/10.1186/s13075-017-1271-7

21. Haque S, Alexander MY, Bruce IN (2012) Endothelial progenitor cells: a new player in lupus? Arthritis Res Ther 14:203. https://doi.org/10.1186/ar3700

22. Nathan NO, Mørch LS, Wu CS, Olsen J, Hetland ML, Li J, Rom AL (2019) Rheumatoid arthritis and risk of spontaneous abortion: a Danish nationwide cohort study. Rheumatology (Oxford) 59:1984–1991. https://doi.org/10.1093/rheumatology/kez565

23. Blagojevic J, AlOdhaibi KA, Aly AM et al (2019) Pregnancy in women with systemic lupus erythematosus: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23:1179–1187

24. Moroni G, Ponticelli C (2016) Pregnancy in women with systemic lupus erythematosus (SLE). Eur J Intern Med 32:7–12

25. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinschenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173

26. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1444–1452. https://doi.org/10.1212/wnl.33.11.1444

27. Giovannoni G, Tomic D, Bright JR, Havrdová E (2017) “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23:1179–1187

28. Bertino E, Di Nicola P, VaraIda A, et al (2012) Neonatal growth charts. In: Journal of Maternal-Fetal and Neonatal Medicine. pp. 67–69

29. Davey DA, MacGillivray I (1988) The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 158:892–898. https://doi.org/10.1016/0002-9378(88)90090-7

30. Cohain JS, Buxbaum RE, Mankuta D (2017) Spontaneous first trimester miscarriage rates per woman among parous women with 1 or more pregnancies of 24 weeks or more. BMC Pregnancy Childbirth 17:437. https://doi.org/10.1186/s12884-017-1620-1

31. De Carolis S, Moretti S, Rizzo F et al (2019) Autoimmunity in obstetrics and autoimmune diseases in pregnancy. Best Pract Res Clin Obstet Gynaecol 60:66–76

32. Marder W, Littlejohn EA, Somers EC (2016) Pregnancy and autoimmune connective tissue diseases. Best Pract Res Clin Rheumatol 30:63–80

33. Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Buxtell PA (2019) UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol 19:106–114

34. Savvidou MD, Xiao Q, Kahiara C, Anderson JM, Nicolaides KH (2008) Maternal circulating endothelial progenitor cells in normal singleton and twin pregnancy. Am J Obstet Gynecol 198:414.e1–414.e5. https://doi.org/10.1016/j.ajog.2007.10.800

35. Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO (2014) JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 71:596–602. https://doi.org/10.1001/jamaneurol.2014.63

36. Moussavi SH, Abroun S, Zarrabi M, Ahmadipanah M (2017) The effect of maternal and infant factors on cord blood yield. Pediatr Blood Cancer 64(7). https://doi.org/10.1002/pbc.26381

37. Al-Sweedan SA, Musalam L, Obeidat B (2013) Factors predicting the hematopoietic stem cells content of the umbilical cord blood. Transfus Apher Sci 48:247–252. https://doi.org/10.1016/j.transci.2013.01.003

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.